From: Acceptance of COVID-19 vaccination among maintenance hemodialysis patients: an Egyptian survey study
Variables | Total | VA | VH | VR | P |
---|---|---|---|---|---|
(n = 237) | (n = 138) | (n = 63) | (n = 36) | ||
Age (years), mean ± SD | 45.25 ± 18.27 | 46.77 ± 17.88 | 41.44 ± 17.32 | 46.08 ± 20.77 | 0.14 |
Sex | Â | Â | Â | Â | Â |
 Females | 114 (48.1) | 62 (44.9) | 35 (55.6) | 17 (47.2) | 0.375 |
 Males | 123 (51.9) | 76 (55.1) | 28 (44.4) | 19 (52.8) |  |
Marital status | Â | Â | Â | Â | Â |
 Single/divorced/widowed | 52 (21.9) | 31 (22.5) | 14 (22.2) | 7 (19.4) | 0.925 |
 Married | 185 (78.1) | 107 (77.5) | 49 (77.8) | 29 (80.6) |  |
Occupation | Â | Â | Â | Â | Â |
 Unemployed | 119 (50.2) | 61 (44.2) | 35 (55.6) | 23 (63.9) | 0.018* |
 Employed | 42 (17.7) | 24 (17.4) | 13 (20.6) | 5 (13.9) |  |
 Retired | 28 (11.8) | 16 (11.6) | 7 (11.1) | 5 (13.9) |  |
 Cannot work due to disability | 45 (19) | 34 (24.6) | 8 (12.7) | 3 (8.3) |  |
 Student | 3 (1.3) | 3 (2.2) | 0 | 0 |  |
Education level | Â | Â | Â | Â | Â |
 Not educated | 52 (21.9) | 34 (24.6) | 7 (11.1) | 11 (30.6) | 0.215 |
 Low school | 30 (12.7) | 17 (12.3) | 7 (11.1) | 6 (16.7) |  |
 Middle school | 90 (38.0) | 43 (31.2) | 35 (55.6) | 12 (33.3) |  |
 High school | 2 (0.8) | 1 (0.7) | 1 (1.6) | 6 (16.7) |  |
 College degree | 60 (25.3) | 41 (29.7) | 13 (20.6) | 1 (2.8) |  |
 Post-graduate | 3 (1.3) | 2 (1.4) |  |  |  |
Governorate | Â | Â | Â | Â | Â |
 Assiut | 148 (62.4) | 87 (63) | 36 (57.1) | 25 (69.4) | 0.467 |
 Dakahlia | 89 (37.6) | 51 (37) | 27 (42.9) | 11 (30.6) |  |
Residence | Â | Â | Â | Â | Â |
 Rural | 149 (62.9) | 79 (57.2) | 40 (63.5) | 30 (83.3) | 0.016* |
 Urban | 88 (37.1) | 59 (42.8) | 23 (36.5) | 6 (16.7) |  |
Active lifestyle | 158 (66.7) | 92 (66.7) | 42 (66.7) | 24 (66.7) | 1 |
Smoking habit | Â | Â | Â | Â | Â |
 Nonsmoker | 193 (81.4) | 111 (80.4) | 55 (87.3) | 27 (75) | 0.277 |
 Former smoker | 25 (10.5) | 15 (10.9) | 5 (7.9) | 5 (13.9) |  |
 Current Smoker | 19 (8) | 12 (8.7) | 3 (4.8) | 4 (11.1) |  |
Family income | Â | Â | Â | Â | Â |
 Not enough | 61 (25.7) | 31 (22.5) | 18 (28.6) | 12 (33.3) | 0.132 |
 Enough with no saving | 156 (65.8) | 91 (65.9) | 44 (69.8) | 21 (58.3) |  |
 Enough and saving | 20 (8.4) | 16 (11.6) | 1 (1.6) | 3 (8.3) |  |
Causes of chronic renal failure | Â | Â | Â | Â | Â |
 Amyloidosis | 1 (0.4) | 0 | 1 (1.6) | 0 | 0.921 |
 Analgesic nephropathy | 10 (4.2) | 4 (2.9) | 5 (7.9) | 1 (2.8) |  |
 Chronic pyelonephritis | 5 (2.1) | 2 (1.4) | 2 (3.2) | 1 (2.8) |  |
 Congenital kidney abnormalities | 17 (7.2) | 11 (8) | 5 (7.9) | 1 (2.8) |  |
 Diabetes mellitus | 9 (3.8) | 2 (1.4) | 5 (7.9) | 2 (5.6) |  |
 Glomerulonephritis | 9 (3.8) | 5 (3.6) | 2 (3.2) | 2 (5.6) |  |
 Hypertension | 65 (27.4) | 45 (32.6) | 12 (19) | 8 (22.2) |  |
 Hypertension and diabetes mellitus | 18 (7.6) | 12 (8.7) | 4 (6.3) | 2 (5.6) |  |
 Hypovolemia | 5 (2.1) | 2 (1.4) | 3 (4.8) | 0 |  |
 Nephrolithiasis | 6 (2.5) | 4 (2.9) | 1 (1.6) | 1 (2.8) |  |
 Pregnancy related | 4 (1.7) | 2 (1.4) | 1 (1.6) | 1 (2.8) |  |
 Schistosomiasis | 1 (0.4) | 1 (0.7) | 0 | 0 |  |
 Unknown | 87 (36.7) | 48 (34.8) | 22 (34.9) | 17 (47.2) |  |
Disease duration, months, median (min–max) | 36 (1–288) | 36 (1–288) | 36 (1.2–204) | 48 (1.2–192) | 0.363 |
Self-rated overall disease activity, median (min–max) | 5 (0–10) | 5 (0–10) | 5 (0–9) | 5 (1–10) | 0.599 |
Therapeutic data | Â | Â | Â | Â | Â |
 None | 31 (13.1) | 17 (12.3) | 7 (11.1) | 7 (19.4) | 0.458 |
 Erythropoietin | 151 (63.7) | 88 (63.8) | 43 (68.3) | 20 (55.6) | 0.451 |
 Iron supplementation | 153 (64.6) | 89 (64.5) | 40 (63.5) | 24 (66.7) | 0.95 |
 Calcium supplementation | 162 (68.4) | 97 (70.3) | 43 (68.3) | 22 (61.1) | 0.575 |
 Vitamin D | 117 (49.4) | 75 (54.3) | 28 (44.4) | 14 (38.9) | 0.17 |
 Calcimimetics | 14 (5.9) | 7 (5.1) | 6 (9.5) | 1 (2.8) | 0.32 |
 Aluminum hydroxide | 5 (2.1) | 2 (1.4) | 1 (1.6) | 2 (5.6) | 0.296 |
 Antihypertensives drugs | 132 (55.7) | 78 (56.5) | 39 (61.9) | 15 (41.7) | 0.144 |
 Antidiabetic drugs | 33 (13.9) | 19 (13.8) | 7 (11.1) | 7 (19.4) | 0.515 |
Adherence to therapy | 204 (86.1) | 120 (87) | 54 (85.7) | 30 (83.3) | 0.852 |
Associated comorbidities | Â | Â | Â | Â | Â |
 Diabetes | 42 (17.7) | 24 (17.4) | 11 (17.5) | 7 (19.4) | 0.958 |
 Hypertension | 167 (70.5) | 101 (73.2) | 46 (73.0) | 20 (55.6) | 0.105 |
 Chronic lung disease | 5 (2.1) | 4 (2.9) | 1 (1.6) | 0 | 0.53 |
 Ischemic heart disease | 13 (5.5) | 8 (5.8) | 3 (4.8) | 2 (5.6) | 0.956 |
COVID-19 infection | |||||
History of COVID-19 infection | 44 (18.6) | 27 (19.6) | 11 (17.5) | 6 (16.7) | 0.893 |
 Duration, days, median (min–max) | 9.5 (0–120) | 9 (0–25) | 14 (1–120) | 4 (1–14) | 445 |
 Hospitalization | 13 (29.6) | 8 (29.6) | 5 (45.5) | 0 | 0.202 |
 ICU admission | 1 (2.3) | 0 | 1 (9.5) | 0 | 0.256 |
COVID-19 among relatives | 65 (27.4) | 41 (29.7) | 12 (19) | 12 (33.3) | 0.202 |
 Hospitalization | 21 (8.9) | 14 (10.1) | 2 (3.2) | 5 (13.9) | 0.141 |
 Death | 20 (8.4) | 13 (9.4) | 3 (4.8) | 4 (11.1) | 0.449 |